Articles Comments

Health and Diseases » Cervical Dysplasia » Adding Imiquimod (Aldara) to standard cervical dysplasia treatment won’t prevent its recurrence

Adding Imiquimod (Aldara) to standard cervical dysplasia treatment won’t prevent its recurrence

Immunomodulator medication which has the active ingredient of imiquimod (INN) has been approved by the FDA to treat premalignant of skin, cutaneous condition of subtype of basal cell carcinoma, and external genital warts with the side effects that should be considered.

Due to genital warts, this drug may enhance the immune response, the researchers hypothesized that when adding this drug to current standard cervical dysplasia treatment (freezing, electrosurgery, or scalpels) may help from its recurring.

However, after 2 years of randomized trial in 56 women with cervical dysplasia, which half of them also received topical imiquimod (Aldara) over roughly two weeks, the researchers said that imiquimod no help in preventing from recurrence.

While 4 women in both of groups showed recurrence that involved at least one HPV type matching the type present at study entry, those in imiquimod group had significantly more headaches, fatigue, fever, myalgias, rigors and vaginal discharge.

The results of study reported in the American Journal of Obstetrics and Gynecology on July 11, 2011.

Filed under: Cervical Dysplasia · Tags: , , , , ,

Leave a Reply

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>